Sponsors / TTIPF
TTIPF

Thiogenesis Therapeutics, Inc.

Company identity has not yet been verified

Browse linked trials and recorded changes, or follow this company for updates.

Follow company
2Trials in this database
6Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

Completion dates · Pro

Which trial dates moved later?

Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features

Included trials

Check company identity source
TrialSponsorPhaseStatusPrimary completion
A Study to Assess TTI-0102 vs Placebo in MELAS PatientsNCT06644534Thiogenesis Therapeutics, Inc.Phase 2Completed2026-01-12Actual
A Dose-ranging Study of TTI-0102 in Adults and Children With Leigh Syndrome Spectrum (LSS)NCT06990984Thiogenesis Therapeutics, Inc.Phase 2Not yet recruiting2027-06Estimated

Latest recorded trial changes

A Study to Assess TTI-0102 vs Placebo in MELAS Patients

NCT06644534 · Thiogenesis Therapeutics, Inc.

· 5 fields changed

Participant count type changed

− Before

Estimated

+ After

Actual

Enrollment · participant count changed

− Before

12 participants (planned)

+ After

9 participants (actual)

Completion date type changed

− Before

Estimated

+ After

Actual

Primary completion date changed

− Before

30 Apr 2026

+ After

12 Jan 2026

Recruitment status changed

− Before

Recruiting

+ After

Completed

Check registry source